Targeting Neuroinflammation to Alleviate Chronic Olfactory Dysfunction in Long COVID: A Role for Investigating Disease-Modifying Therapy (DMT)?

Chronic olfactory dysfunction after SARS-CoV-2 infection occurs in approximately 10% of patients with COVID-19-induced anosmia, and it is a growing public health concern. A regimen of olfactory training and anti-neuroinflammatory therapy with co-ultramicronized palmitoylethanolamide with luteolin (u...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Stadio, Arianna, Bernitsas, Evanthia, La Mantia, Ignazio, Brenner, Michael J., Ralli, Massimo, Vaira, Luigi Angelo, Colizza, Andrea, Cavaliere, Carlo, Laudani, Matteo, Frohman, Teresa C., De Vincentiis, Marco, Frohman, Elliot M., Altieri, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863729/
https://www.ncbi.nlm.nih.gov/pubmed/36676175
http://dx.doi.org/10.3390/life13010226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863729/
https://www.ncbi.nlm.nih.gov/pubmed/36676175
http://dx.doi.org/10.3390/life13010226

Ejemplares similares